# Article information:

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis - PubMed
<https://pubmed-ncbi-nlm-nih-gov-443.webvpn.bjmu.edu.cn/27505670/>

# Article summary:

1. EZH2 and BCL6 cooperate to assemble a CBX8-BCOR complex to repress bivalent promoters, which is necessary for germinal center formation and lymphomagenesis.

2. The chromodomain protein CBX8 binds to H3K27me3 at bivalent promoters and is required for stable association of the complex and the resulting histone modifications.

3. Oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development, and targeting both repressors results in enhanced anti-lymphoma activity in DLBCLs.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

This article provides a comprehensive overview of the role of EZH2 and BCL6 in mediating the humoral immune response, driving germinal center formation, and promoting lymphomagenesis through formation of bivalent chromatin domains at critical GC B cell promoters. The authors provide evidence that the actions of EZH2 require site-specific binding by the BCL6 transcriptional repressor as well as the presence of a non-canonical PRC1-BCOR-CBX8 complex. Furthermore, they demonstrate that oncogenic BCL6 and EZH2 cooperate to accelerate DLBCL development, suggesting that combinatorial targeting of these repressors could result in enhanced anti-lymphoma activity in DLBCLs.

The article appears to be reliable overall; however, there are some potential biases worth noting. For example, it does not explore any counterarguments or present both sides equally; instead it focuses solely on supporting its own claims without considering any alternative perspectives or evidence that may contradict its findings. Additionally, there is no discussion of possible risks associated with targeting these repressors or any mention of potential side effects from such treatments. Finally, while the authors provide evidence for their claims, they do not provide sufficient detail about their methods or data analysis techniques used to support their conclusions.

# Topics for further research:

* Risks associated with targeting EZH2 and BCL6
* Side effects of targeting EZH2 and BCL6
* Alternative perspectives on EZH2 and BCL6
* Data analysis techniques for studying EZH2 and BCL6
* Counterarguments to EZH2 and BCL6 role in lymphomagenesis
* PRC1-BCOR-CBX8 complex and EZH2

# Report location:

<https://www.fullpicture.app/item/8c781048a05ca27ccdeb11fefe165e50>